OBIO PE Ratio & Valuation, Is OBIO Overvalued

Historical Valuation

Orchestra Biomed Holdings Inc (OBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 77.98 is considered Fairly compared with the five-year average of -2.80. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.84 to 5.43 according to relative valuation method.

Relative Value

Fair Zone

0.84-5.43

Current Price：4.64

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Orchestra Biomed Holdings Inc (OBIO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Orchestra Biomed Holdings Inc (OBIO) has a current Price-to-Book (P/B) ratio of 5.56. Compared to its 3-year average P/B ratio of 33.00, the current P/B ratio is approximately -83.14% higher. Relative to its 5-year average P/B ratio of 19.71, the current P/B ratio is about -71.76% higher. Orchestra Biomed Holdings Inc (OBIO) has a Forward Free Cash Flow (FCF) yield of approximately -24.98%. Compared to its 3-year average FCF yield of -24.60%, the current FCF yield is approximately 1.55% lower. Relative to its 5-year average FCF yield of -23.94%, the current FCF yield is about 4.33% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for OBIO competitors is 23.58, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO.O) exhibits a P/S ratio of 77.98, which is 230.69% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of OBIO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of OBIO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is OBIO currently overvalued or undervalued?

What is Orchestra Biomed Holdings Inc (OBIO) fair value?

OBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Orchestra Biomed Holdings Inc (OBIO) is between 0.84 to 5.43 according to relative valuation method.

How does OBIO's valuation metrics compare to the industry average?

The average P/S ratio for OBIO's competitors is 23.58, providing a benchmark for relative valuation. Orchestra Biomed Holdings Inc Corp (OBIO) exhibits a P/S ratio of 77.98, which is 230.69% above the industry average. Given its robust revenue growth of -12.77%, this premium appears unsustainable.

What is the current P/B ratio for Orchestra Biomed Holdings Inc (OBIO) as of Mar 11 2026?

As of Mar 11 2026, Orchestra Biomed Holdings Inc (OBIO) has a P/B ratio of 5.56. This indicates that the market values OBIO at 5.56 times its book value.

What is the current FCF Yield for Orchestra Biomed Holdings Inc (OBIO) as of Mar 11 2026?

As of Mar 11 2026, Orchestra Biomed Holdings Inc (OBIO) has a FCF Yield of -24.98%. This means that for every dollar of Orchestra Biomed Holdings Inc's market capitalization, the company generates -24.98 cents in free cash flow.

What is the current Forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO) as of Mar 11 2026?

As of Mar 11 2026, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/E ratio of -2.73. This means the market is willing to pay $-2.73 for every dollar of Orchestra Biomed Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Orchestra Biomed Holdings Inc (OBIO) as of Mar 11 2026?

As of Mar 11 2026, Orchestra Biomed Holdings Inc (OBIO) has a Forward P/S ratio of 77.98. This means the market is valuing OBIO at $77.98 for every dollar of expected revenue over the next 12 months.

OBIO Valuation